Atria Investments Inc Decreases Position in Colgate-Palmolive (NYSE:CL)

Atria Investments Inc cut its stake in shares of Colgate-Palmolive (NYSE:CL) by 1.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,785 shares of the company’s stock after selling 1,280 shares during the period. Atria Investments Inc’s holdings in Colgate-Palmolive were worth $6,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Assetmark Inc. raised its position in Colgate-Palmolive by 295.1% during the fourth quarter. Assetmark Inc. now owns 16,280 shares of the company’s stock valued at $1,480,000 after purchasing an additional 12,160 shares during the period. Cypress Capital Group raised its position in Colgate-Palmolive by 12.6% during the fourth quarter. Cypress Capital Group now owns 29,647 shares of the company’s stock valued at $2,695,000 after purchasing an additional 3,307 shares during the period. Jag Capital Management LLC raised its position in Colgate-Palmolive by 0.7% during the fourth quarter. Jag Capital Management LLC now owns 33,773 shares of the company’s stock valued at $3,070,000 after purchasing an additional 227 shares during the period. Commerzbank Aktiengesellschaft FI raised its position in Colgate-Palmolive by 32.4% during the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 18,087 shares of the company’s stock valued at $1,644,000 after purchasing an additional 4,422 shares during the period. Finally, Synergy Investment Management LLC purchased a new stake in Colgate-Palmolive during the fourth quarter valued at approximately $75,000. 80.41% of the stock is currently owned by hedge funds and other institutional investors.

Colgate-Palmolive Stock Up 1.7 %

Shares of NYSE CL opened at $93.30 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.58 and a debt-to-equity ratio of 13.40. The stock has a market capitalization of $75.72 billion, a PE ratio of 26.51, a price-to-earnings-growth ratio of 4.20 and a beta of 0.44. The stock’s fifty day simple moving average is $88.74 and its two-hundred day simple moving average is $95.26. Colgate-Palmolive has a 12-month low of $85.32 and a 12-month high of $109.30.

Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, January 31st. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.01. Colgate-Palmolive had a return on equity of 477.77% and a net margin of 14.38%. During the same quarter in the previous year, the firm posted $0.87 EPS. As a group, analysts expect that Colgate-Palmolive will post 3.75 EPS for the current fiscal year.

Colgate-Palmolive Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, February 14th. Shareholders of record on Tuesday, January 21st were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 2.14%. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 56.82%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CL shares. Morgan Stanley cut their target price on Colgate-Palmolive from $111.00 to $104.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. JPMorgan Chase & Co. cut their target price on Colgate-Palmolive from $103.00 to $97.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Stifel Nicolaus cut their target price on Colgate-Palmolive from $95.00 to $93.00 and set a “hold” rating on the stock in a research note on Monday, February 3rd. Piper Sandler cut their target price on Colgate-Palmolive from $121.00 to $112.00 and set an “overweight” rating on the stock in a research note on Monday, January 6th. Finally, UBS Group cut their target price on Colgate-Palmolive from $104.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $101.61.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.